Ferring and Rebiotix Present Landmark Phase 3 Data Demonstrating Superior Efficacy of Investigational RBX2660 Versus Placebo to Reduce Recurrence of C. difficile Infection
Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today presented results from the pivotal Phase 3 PUNCH™ CD3 clinical trial, demonstrating superior efficacy and consistent safety of single-dose RBX2660 in reducing recurrence of Clostridioides difficileinfection (CDI) over placebo. RBX2660 is an investigational, potential first-in-class microbiota-based live biotherapeutic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210521005335/en/
The trial, presented today at Digestive Disease Week® (DDW) 2021, successfully met its primary endpoint. RBX2660 demonstrated superior efficacy versus placebo (70.4% and 58.1%, respectively) at 8 weeks post treatment, with a comparable safety profile to placebo. RBX2660 results demonstrated statistical significance with a 98.6% posterior probability of superiority, which exceeded the 97.5% minimum threshold. In addition to these outcomes, RBX2660 provided a relative reduction of recurrence of 29.4% compared to placebo. The majority of treatment emergent adverse events (TEAEs) for RBX2660 were similar to placebo, and mild to moderate in nature. These data add to the large body of evidence showing consistent efficacy and safety in patients who have received RBX2660, which may help address the unmet need for patients who suffer from this debilitating and potentially deadly recurrent infection.
“C. difficile infection is a global public health threat that requires immediate action to halt the unrelenting cycle of recurrence. While necessary to treat initial infection, antibiotics are also a predominant risk factor for recurrence because they can disrupt the gut microbiome, leaving the current treatment paradigm for recurrent infection incomplete,” said Paul Feuerstadt, MD, FACG, AGAF, PACT Gastroenterology, Hamden, Conn., Assistant Clinical Professor of Medicine, Yale University School of Medicine, New Haven, Conn., and RBX2660 clinical trial investigator. “These Phase 3 RBX2660 results, as part of the overall clinical development program, show consistent efficacy as early as a first recurrence of C. difficile infection by delivering a broad consortium of live microbes to the area of active infection.”
“People who suffer from C. difficile infection are devastated when they experience recurrence. Patients have told me that they felt hopeless when the infection returned again and again despite multiple courses of antibiotic treatment. They believed that the infection would never go away,” said Christine Lee, MD, FRCPC, Clinical Professor, Department of Pathology and Laboratory Medicine, UBC Faculty of Medicine, Medical Microbiologist and Researcher, Island Health, Vancouver, and RBX2660 clinical trial investigator who presented the data at DDW. "The findings from this pivotal Phase 3 trial of RBX2660 are very encouraging to both patients and healthcare providers, providing hope this potential new treatment could make a meaningful difference in the lives of patients with recurrent C. difficile infection."
The RBX2660 program is the largest and most robust clinical program ever conducted in the field of microbiome-based therapeutics. The decade-long development program consists of six trials with more than 1,000 patients enrolled; two of these trials are the only ones in the field to include two years of follow-up.
“These Phase 3 results are a testament to a decade of robust clinical research to help address a significant unmet patient need,” said Lee Jones, President and CEO of Rebiotix, a Ferring Company. We are deeply grateful to the patients and clinicians for their years of dedication to this program.”
“At Ferring, we are dedicated to helping people live better lives,” said Per Falk, President of Ferring Pharmaceuticals. “We look forward to sharing our data with the U.S. FDA as we believe, based on the totality of evidence, RBX2660 holds the potential to be an improvement over the standard of care alone for tens of thousands of patients affected every year by recurrent C. difficile infection.”
About the PUNCH™ CD3 Clinical Trial (Clinicaltrials.gov identifier: NCT03244644)
PUNCH™ CD3 is a Phase 3, prospective, multicenter, randomized, double-blinded, placebo-controlled clinical trial evaluating the efficacy and safety of RBX2660 vs. placebo in preventing rCDI. The study included adults ages 18 or older who had at least one recurrence after a primary episode of CDI. Participants were followed up to 8 weeks for the efficacy analysis, and up to six months for the safety analysis.
RBX2660 is a potential first-in-class microbiota-based live biotherapeutic being studied to deliver a broad consortium of diverse microbes to the gut to reduce recurrent C. difficile infection. RBX2660 has been granted Fast Track, Orphan, and Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA). The pivotal Phase 3 program builds on nearly a decade of research with robust clinical and microbiome data collected over six controlled clinical trials with more than 1,000 participants.
About the microbiome and C. difficile infection
The microbiome is a highly-diverse microbial community that plays an essential role in human health. There is a growing body of evidence that shows when there is a disruption of the composition and/or diversity of the gut microbiome, there may be an associated risk for serious illnesses, such as C. difficile infection.
C. difficile is a bacterium that causes debilitating symptoms such as severe diarrhea, fever, stomach tenderness or pain, loss of appetite, nausea and colitis (an inflammation of the colon).1 Estimated to cause up to half a million illnesses and thousands of deaths annually in the U.S. alone every year, C. difficile infection is considered an urgent threat to public health by the CDC and can lead to severe complications, including hospitalization, surgery, sepsis and death.1,2C. difficile infection is often the start of a vicious cycle of recurrence, causing a significant burden for patients and the healthcare system.3,4 The use of antibiotics has been shown to disrupt the ecology of the gut microbiome, and are a predominant risk factor for C. difficile recurrence – occurring in up to 35% of patients after initial C. difficile infection diagnosis.5,6,7 After the first recurrence, it has been estimated that up to 60% of patients may develop a subsequent recurrence.8
About Ferring Pharmaceuticals
Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs approximately 6,500 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries. Learn more at www.ferring.com, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.
Ferring is committed to exploring the crucial link between the microbiome and human health, beginning with the threat of recurrent C. difficile infection. With the 2018 acquisition of Rebiotix and several other alliances, Ferring is a world leader in microbiome research, developing novel microbiome-based therapeutics to address significant unmet needs and help people live better lives. Connect with us on our dedicated microbiome therapeutics development channels on Twitter and LinkedIn.
Rebiotix Inc, a Ferring Company, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of challenging diseases. Rebiotix has a diverse pipeline of investigational drug products built on its pioneering microbiota-based MRT™ drug platform. The platform consists of investigational drug technologies designed to potentially rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient’s intestinal tract. For more information on Rebiotix and its pipeline of human microbiome-directed therapies for diverse disease states, visit www.rebiotix.com, or connect with us on Twitter, Facebook, LinkedIn and YouTube.
Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is a fully virtual meeting from May 21-23, 2021. The meeting showcases more than 2,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org.
- Centers for Disease Control and Prevention. What Is C. Diff? 17 Dec. 2018. Available at: https://www.cdc.gov/cdiff/what-is.html.
- Centers for Disease Control and Prevention. Biggest Threats and Data, 14 Nov. 2019. Available at: https://www.cdc.gov/drugresistance/biggest-threats.html.
- Centers for Disease Control and Prevention. 24 June 2020. Available at: https://www.cdc.gov/drugresistance/pdf/threats-report/clostridioides-difficile-508.pdf.
- Feuerstadt P, et al. J Med Econ. 2020;23(6):603-609.
- Lessa FC, Mu Y, Bamberg WM, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med. 2015;372(9):825-834.
- Cornely OA, et al. Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin. Clinical Infectious Diseases. 2012;55(S2):S154–61.
- Langdon A, Crook N, Dantas G. The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation. Genome Med. 2016;8(1):39.
- Leong C, Zelenitsky S. Treatment strategies for recurrent Clostridium difficile infection. Can J Hosp Pharm. 2013;66(6):361-368.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
For more information, please contact
Director, Brand Communications
Communications & Digital Innovation
Associate Director, Marketing and Communications
Rebiotix Inc., a Ferring Company
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Manx Telecom Partners With Mavenir to Transform Its Mobile Voice and Data Network and Trials Open RAN With Mavenir’s Leading Cloud-Native Solutions24.6.2021 10:00:00 CEST | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, announces today that Isle of Man-basedcommunications service provider, Manx Telecom will be using the MAVcore solution to deliver both voice (VoLTE) and data networks (Packet Core). Mavenir will be delivering and deploying an end-to-end solution to Manx Telecom for its On-Island and OV businesses, comprising cloud-native virtualised IMS and Packet Cores. In addition, Manx Telecom will use the MAVair solution to undertake an Open RAN trial. Manx Telecom selected Mavenir as the best fit to meet the company’s overall requirement today and its future architecture needs for IMS, Packet Core and RAN solutions. The MAVcore family includes Mavenir’s global leading VoLTE IMS and voice services delivering VoLTE based virtualised IMS solution including VoLTE roaming and PCRF capability, and its leading-edge Packet Core solution deliver
Philip Morris International: New Study Shows Near-Doubling in Counterfeit Cigarettes in the European Union Drives Increase of Total Illicit Consumption in 202024.6.2021 10:00:00 CEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) is calling for public and private representatives to jointly combat illicit trade as a new report produced by KPMG was released on the consumption and flows of illicit cigarettes in 30 European countries—the 27 European Union (EU) member states, as well as U.K., Norway and Switzerland. The study estimates that, while total cigarette consumption continues to decline, the share of illicit cigarettes increased by one half of a percentage point to 7.8% of total consumption in 2020, reaching 34.2 billion cigarettes consumed across the EU 27 member states (EU27). The increase of illicit cigarettes—which consist of contraband, counterfeit, and illicit whites—was driven by an unprecedented 87% surge in counterfeit consumption. The tax loss for governments in the EU27 now amounts to approximately €8.5 billion. The annual study, conducted independently by KPMG and commissioned by PMI, shows how legal and illicit cigarette consumption was impacted
Habu Expands Internationally, Appointing Tim Norris-Wiles as Managing Director EMEA24.6.2021 10:00:00 CEST | Press release
Habu, the Global Innovator in Data Clean Room software, today announced the appointment of industry veteran, Tim Norris-Wiles as the Managing Director of EMEA, as Habu expands internationally and continues to grow its global customer base and business. Building on its tremendous growth in the first half of 2021, Habu’s Data Clean Room software allows brands to benefit from the full value of data in a safe environment, providing measurement, targeting, personalization and access to unique insights for the best marketing results. Through its proprietary methods for cloud data integration and distributed data processing, Habu continues to innovate in ways that enable organizations like Activision, ASICS, Insider and Digital Trends to safely collaborate and fully utilize data within their clean rooms. As the Managing Director of EMEA, Norris-Wiles will oversee Habu’s global growth strategy and execution. He will expand and lead Habu’s international sales organization in Europe and ensure d
Mavenir and Qualcomm Collaborate to Deliver Open RAN 4G/5G Indoor and Outdoor Radio Solutions for Public and Private Networks24.6.2021 10:00:00 CEST | Press release
Mavenir1, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced a collaboration with Qualcomm Technologies, Inc. to develop indoor and outdoor solutions for both private and public network deployments aiming to broaden the choices for Open RAN customers. With rising capacity and coverage demands of 5G, driven by diverse enterprise and consumer requirements, there is a growing need for network densification that harnesses all available spectrum based on flexible and cost-effective radio solutions. This collaboration aims to leverage the power of Mavenir’s software solutions and Qualcomm Technologies’ platform leadership, to deliver a suite of radio solutions based on Open RAN architecture. Mavenir software running on the Qualcomm® 4G and 5G RAN Platforms for Small Cells (FSM), providing a full range of Open RAN software upgradable radio solutions is designed to meet the s
Panasonic Announces Signing of Professional Women’s Tennis Player Naomi Osaka as Brand Ambassador24.6.2021 09:48:00 CEST | Press release
Panasonic Corporation has signed a brand ambassador agreement with professional women's tennis player Naomi Osaka. The period of agreement is two years starting from April 22, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624005399/en/ Panasonic’s Brand Ambassador Naomi Osaka (Graphic: Business Wire) Panasonic sought the agreement with Ms. Osaka after observing that her values and perspectives on society deeply resonate with its own management philosophy, primarily with regard to the following three points: First, Ms. Osaka takes social issues seriously, looking beyond tennis to share her views on what a better society would look like in her own words. The founder of Panasonic, Konosuke Matsushita, held the notion that a stable state of happiness comes only when both mental stability and material prosperity are secured. Based on this idea, the company endeavors to create an ideal society where all of us can enjoy l
Global Banks Preparing to Leverage SWIFT’s New Platform for International Payments Flows24.6.2021 09:00:00 CEST | Press release
Six leading global banks today announced their endorsement for SWIFT’s new transaction management platform and are preparing to use its expanded capabilities to enable new services, improve efficiency and reduce costs when the platform goes live in November 2022. Bank of China, Bank of New York Mellon, BNP Paribas, Citi, Deutsche Bank, and Standard Chartered confirmed their preparations for the platform as the co-operative detailed an ambitious roadmap it will roll out over the next 18 months. New features – including upfront validation of beneficiary details, central management of exceptions, extension of SWIFT’s high-speed gpi rails to lower-value payments and new rich data services based on the ISO 20022 standard – will serve as the building blocks of the enhanced platform. These are integral components of SWIFT’s strategy to facilitate instant and frictionless end-to-end transactions anywhere in the world. The platform evolution builds on extensive work by the SWIFT community in th
ADVA makes virtual routing simple and affordable with Ensemble SmartWAN24.6.2021 09:00:00 CEST | Press release
ADVA (FSE: ADV) today launched its fully featured Ensemble SmartWAN secure networking solution. Integrated into ADVA’s Ensemble network functions virtualization (NFV) suite, the new technology offers enterprises a simple and affordable way to leverage the core benefits of software-defined WAN (SD-WAN), while removing the need for additional virtual network functions (VNFs). Now businesses can deploy a turnkey solution that delivers dynamic virtual routing, centralized management, and full visibility of network topology. With zero-touch provisioning for easy deployment and temperature-hardened servers, Ensemble SmartWAN significantly improves return on investment for applications such as dynamic and fully meshed networking and smart city services. At the same time, it preserves the benefits of an open system that supports runtime additions of new VNFs or user applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210624
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom